CVS Health stock holds as Q3 results lift 2026 outlook

Published on 11/05/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock traded at 73.62 euros on Thursday afternoon. The company raised its full-year adjusted earnings and cash flow outlook after stronger third-quarter results.

CVS raises its 2026 outlook

Third-quarter revenue rose 5.4 percent year over year to 108.4 billion US dollars.
Adjusted earnings per share increased to 2.09 US dollars as Health Care Benefits improved.
Management lifted its adjusted earnings and operating cash flow targets while retaining a cautious view on costs and macroeconomic risks.

CVS Health Corp., US1266501006, Illustration mit AI erstellt.

CVS Health reported stronger third-quarter results on Wednesday, November 4, 2026, and raised its full-year outlook. In its investor release, the company said revenue increased 5.4 percent year over year to 108.4 billion US dollars.

What has changed since our last report

CVS Health stock traded at 73.62 euros on Lang & Schwarz at 16:08 CET on Thursday, November 5, 2026, 9.38 percent below the Xetra close of Wednesday, November 4. The quote was 1.14 percent above the 72.79 euros cited in the preceding report at 15:42 CET on Wednesday.

Adjusted earnings per share reached 2.09 US dollars, up from 1.60 US dollars a year earlier. GAAP diluted earnings per share came to 1.68 US dollars, compared with a loss of 3.13 US dollars in the prior-year quarter. The year-on-year GAAP comparison benefited from the absence of a 5.7 billion US dollar goodwill impairment charge recorded in the third quarter of 2025.

Insurance recovery supports targets

Health Care Benefits adjusted operating income rose to 912 million US dollars from 314 million US dollars. The medical benefit ratio improved to 91.3 percent from 92.8 percent, strengthening the insurance segment's contribution to earnings.

CVS Health now expects full-year adjusted earnings per share of at least 8.20 US dollars, compared with its previous range of 7.90 to 8.10 US dollars. GAAP diluted earnings per share guidance moved to at least 6.98 US dollars from a range of 6.84 to 7.04 US dollars, while operating cash flow guidance increased to at least 15.5 billion US dollars from at least 11.5 billion US dollars.

Management still sees elevated cost trends and potential macroeconomic headwinds as risks for the rest of 2026. Pharmacy and Consumer Wellness revenue declined 2.0 percent in the quarter, leaving reimbursement pressure and regulatory price reductions as issues for investors to monitor.

For investors, the improved insurance margin is becoming a central earnings driver, while pharmacy performance remains a counterweight. The next test is whether lower cost pressure and segment momentum can sustain the raised targets.

For the real-time quote of CVS Health stock, investors can follow the latest trading activity.

The S&P 500 provides the broader market backdrop for US equities as investors assess earnings and interest-rate expectations: current market coverage.

More news and analyses on CVS Health stock.